(P-1101) A Comparative Analysis of Resistance Rates Among Escherichia coli and Klebsiella pneumoniae Isolates Collected from the Gepotidacin Uropathogen Global Surveillance Studies and Phase 3 Uncomplicated Urinary Tract Infection Clinical Studies

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Co-Author(s)

DB

Deborah Butler, PharmD

VP & Head of Emerging Markets Regulatory Affairs at GSK
GSK
London, England, United Kingdom
JB

John Breton, MCM

GSK
Collegeville, Pennsylvania, United States
CK

Cara Kasapidis, BS

GSK
Collegeville, Pennsylvania, United States
DB

Derrek Brown, BS

GSK
Collegeville, Pennsylvania, United States
Amanda Sheets, PhD

Director, Clinical Development
GSK, Collegeville, PA, USA
Collegeville, Pennsylvania, United States
DT

Didem Torumkuney, PhD

Scientific Director
GSK
Brentford, England, United Kingdom
SA

S.J. Ryan Arends, PhD

Element, Iowa City (JMI Laboratories)
North Liberty, Iowa, United States
Rodrigo E. Mendes, PhD (he/him/his)

Director
Element, Iowa City (JMI Laboratories)
North Liberty, IA, United States

Nicole E. Scangarella-Oman, MS (she/her/hers)

Scientific Director
GlaxoSmithKline plc.
Collegeville, Pennsylvania, United States